Patient Convenience Study- NIS RELATE

Launched by BOEHRINGER INGELHEIM · Jul 26, 2016

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• Cohort A:
• • 1. A. Written informed consent prior to participation
• • 2. A. Female and male patients \>= 18 years of age with a diagnosis of non-valvular atrial fibrillation.
• • 3. A. At least 3 months of continuous VKA treatment for stroke prevention prior to baseline assessment.
• • 4. A. Patients switched to Pradaxa® according Summary of Product Characteristics and physician's discretion.
• • OR
• Cohort B:
• • 1. B. Written informed consent prior to participation.
• • 2. B. Female and male patients \>= 18 years of age newly diagnosed with non-valvular atrial fibrillation and no previous treatment for stroke prevention (no use of any oral anticoagulant (OAC) within one year prior to enrolment).
• • 3. B. Stroke prevention treatment initiated with Pradaxa® or VKA according to Summary of Product Characteristics and physician's discretion.
• Exclusion criteria:
• • 1. Contraindication to the use of Pradaxa® or VKA as described in the Summary of Product Characteristics (SmPC).
• • 2. Patients receiving Pradaxa® or VKA for any other condition than stroke prevention in atrial fibrillation.
• • 3. Current participation in any clinical trial of a drug or device.
• • 4. Current participation in an European registry on the use of oral anticoagulation in AF.